for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Co-Diagnostics Inc

CODX.O

Latest Trade

17.47USD

Change

-0.72(-3.96%)

Volume

1,912,656

Today's Range

17.45

 - 

18.70

52 Week Range

0.85

 - 

29.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.19
Open
18.08
Volume
1,912,656
3M AVG Volume
138.40
Today's High
18.70
Today's Low
17.45
52 Week High
29.72
52 Week Low
0.85
Shares Out (MIL)
27.46
Market Cap (MIL)
499.45
Forward P/E
8.83
Dividend (Yield %)
--

Latest Developments

More

Co-Diagnostics Reports Q1 Revenue Of $1.5 Million

Ambalal Sarabhai Enterprises Says Unit's JV Granted Manufacturing License For Covid‐ 19 Rt‐Pcr Test Kits

Co-Diagnostics, Inc. COVID-19 Test Technology Validated For Use On Saliva Samples

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Co-Diagnostics Inc

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Industry

Medical Equipment & Supplies

Contact Info

4049 S Highland Dr

SALT LAKE CITY, UT

84124-1664

United States

+1.801.2789769

http://codiagnostics.com/

Executive Leadership

Dwight H. Egan

Chairman of the Board, President, Chief Executive Officer

Reed L. Benson

Chief Financial Officer, Secretary

Brent Satterfield

Chief Scientific Officer

Eugene Durenard

Independent Director

Edward L. Murphy

Independent Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2018

-0.500

2019

-0.360

2020(E)

2.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
283.76
Price To Book (MRQ)
26.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.01
Return on Equity (TTM)
-44.30

Latest News

Latest News

BRIEF-Co-Diagnostics To Join Russell 2000 And 3000 Indexes

* CO-DIAGNOSTICS (NASDAQ:CODX) TO JOIN RUSSELL 2000® AND 3000® INDEXES Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics To Present At COVID-19 Virtual Conference Hosted By Maxim Group On May 27, 2020

* CO-DIAGNOSTICS, INC. TO PRESENT AT COVID-19 VIRTUAL CONFERENCE HOSTED BY MAXIM GROUP ON MAY 27, 2020 Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics COVID-19 Test Successfully Used To Identify Coronavirus In Cancer Tissue

* CO-DIAGNOSTICS, INC. COVID-19 TEST SUCCESSFULLY USED TO IDENTIFY CORONAVIRUS IN CANCER TISSUE

BRIEF-Co-Diagnostics Reports Q1 Revenue Of $1.5 Million

* CO-DIAGNOSTICS, INC. ANNOUNCES Q1 2020 RESULTS AND PROVIDES MID-SECOND QUARTER UPDATE

BRIEF-Co-Diagnostics Announces Government Approvals And Increased Orders For Covid-19 Test Kits

* CO-DIAGNOSTICS, INC. ANNOUNCES GOVERNMENT APPROVALS AND INCREASED ORDERS FOR COVID-19 TEST KITS

BRIEF-Co-Diagnostics Releases COVID-19 Test Performance Data

* CO-DIAGNOSTICS, INC. RELEASES COVID-19 TEST PERFORMANCE DATA: CONSISTENTLY DEMONSTRATES 100% SENSITIVITY AND 100% SPECIFICITY ACROSS INDEPENDENT EVALUATIONS Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics Announces Expansion Of COVID-19 Test Orders In The United States

* CO-DIAGNOSTICS, INC. ANNOUNCES EXPANSION OF COVID-19 TEST ORDERS IN THE UNITED STATES Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics, Inc. COVID-19 Test Technology Validated For Use On Saliva Samples

* CO-DIAGNOSTICS, INC. COVID-19 TEST TECHNOLOGY VALIDATED FOR USE ON SALIVA SAMPLES

BRIEF-Co-Diagnostics Says Contracts With Promega For Covid-19 Test Manufacturing

* CO-DIAGNOSTICS, INC. CONTRACTS WITH PROMEGA CORP FOR COVID-19 TEST MANUFACTURING AS COMPANY EXPANDS DOMESTIC CUSTOMER BASE Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics Receives FDA Emergency Use Authorization For Covid-19 Test

* CO-DIAGNOSTICS, INC RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR COVID-19 TEST

BRIEF-Co-Diagnostics Completes Successful Clinical Evaluation Required For FDA Emergency Use Authorization

* CO-DIAGNOSTICS, INC COMPLETES SUCCESSFUL CLINICAL EVALUATION REQUIRED FOR FDA EMERGENCY USE AUTHORIZATION

BRIEF-Co-Diagnostics JV Cosara First Indian Company To Receive License For Covid-19 Diagnostic

* CO-DIAGNOSTICS JV COSARA FIRST INDIAN COMPANY TO RECEIVE LICENSE FOR COVID-19 DIAGNOSTIC

Co-Diagnostics says new FDA policy to help expand use of COVID-19 test

Co-Diagnostics Inc said on Tuesday the U.S. Food and Drug Administration's new policy to expand the availability of COVID-19 tests would allow the medical test maker's tests to be distributed to a wide array of U.S. labs.

Co-Diagnostics says new FDA policy to help expand use of COVID-19 test

Co-Diagnostics Inc said on Tuesday the U.S. Food and Drug Administration's new policy to expand availability of COVID-19 tests will allow the medical test maker's tests to be distributed to a wide array of U.S. labs.

BRIEF-Co-Diagnostics - FDA Policy Change To Allow Rapid Domestic Expansion Of Co-Diagnostics Covid-19 Test

* FDA POLICY CHANGE TO ALLOW RAPID DOMESTIC EXPANSION OF CO-DIAGNOSTICS COVID-19 TEST

BRIEF-Precheck Health To Exclusively Distribute Coronavirus Covid-19 Test In Ecuador For Co-Diagnostics

* PRECHECK HEALTH TO EXCLUSIVELY DISTRIBUTE CORONAVIRUS COVID-19 TEST IN ECUADOR FOR CO-DIAGNOSTICS, INC.

BRIEF-Precheck Health Services Enters Into Distribution Agreement With Co-Diagnostics

* PRECHECK HEALTH SERVICES - ON MARCH 9, 2020, ENTERED INTO DISTRIBUTION AGREEMENT WITH CO-DIAGNOSTICS INC - SEC FILING

BRIEF-Co-Diagnostics Inc Reports Additional Demand For Coronavirus Test Shipments

* CO-DIAGNOSTICS, INC. REPORTS ADDITIONAL DEMAND FOR CORONAVIRUS TEST SHIPMENTS

BRIEF-Co-Diagnostics Inc To Provide Covid-19 Tests To US CLIA Labs Following FDA Policy Change

* CO-DIAGNOSTICS, INC. TO PROVIDE COVID-19 TESTS TO US CLIA LABS FOLLOWING FDA POLICY CHANGE

BRIEF-Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-The-Market

* CO-DIAGNOSTICS ANNOUNCES $4.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up